568 related articles for article (PubMed ID: 30053126)
21. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
22. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma.
Li R; Gao K; Luo H; Wang X; Shi Y; Dong Q; Luan W; You Y
J Exp Clin Cancer Res; 2014 Jan; 33(1):9. PubMed ID: 24438238
[TBL] [Abstract][Full Text] [Related]
23. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
Wang H; Li L; Yin L
Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
[TBL] [Abstract][Full Text] [Related]
24. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
Chang WH; Lai AG
Mol Med; 2019 Nov; 25(1):46. PubMed ID: 31684858
[TBL] [Abstract][Full Text] [Related]
25. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
[TBL] [Abstract][Full Text] [Related]
27. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
28. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome analyses reveal molecular mechanisms underlying phenotypic differences among transcriptional subtypes of glioblastoma.
Pan YB; Wang S; Yang B; Jiang Z; Lenahan C; Wang J; Zhang J; Shao A
J Cell Mol Med; 2020 Apr; 24(7):3901-3916. PubMed ID: 32091665
[TBL] [Abstract][Full Text] [Related]
32. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
35. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
Chang WH; Lai AG
BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
37. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
38. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
39. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.
Rutledge WC; Kong J; Gao J; Gutman DA; Cooper LA; Appin C; Park Y; Scarpace L; Mikkelsen T; Cohen ML; Aldape KD; McLendon RE; Lehman NL; Miller CR; Schniederjan MJ; Brennan CW; Saltz JH; Moreno CS; Brat DJ
Clin Cancer Res; 2013 Sep; 19(18):4951-60. PubMed ID: 23864165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
